Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Can we identify allergic rhinitis from administrative data: A validation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tramadol use in Norway: A register-based population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Multi-centre, multi-database studies with common protocols: Lessons learnt from the IMI PROTECT project

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: National reimbursement policies in Denmark were changed in November 2010 favouring a shift in angiotensin-II receptor blocker (ARB) treatment to generic losartan for heart failure (HF) patients. We examined how changes in reimbursement policies affected the fraction of HF patients up-titrated to optimal or suboptimal ARB dosage.

METHODS: A historical cohort study was performed including HF patients with at least one prescription of ARB in the months of May-Jul 2010 (baseline). Patients were considered up-titrated at doses 100, 16 or 160 mg for losartan, valsartan and candesartan, respectively. Individual-level linkage of nationwide registries of hospitalization and drug dispensing in Denmark was used to describe patterns of ARB prescriptions and estimate dosage before and after November 2010. Logistic regression models were used to assess the probability for being up-titrated in the period.

RESULTS: Of 6036 individuals included (mean age 73.5 [standard deviation 11.2] years; 51% males), 3346 (55.4%) used losartan, 541 (9.0%) valsartan and 2149 (35.6%) candesartan at inclusion, respectively. 2887 (47.8%) were up-titrated at baseline (May-Jul 2010), followed by 2878 (48.2%) in the three months before the policy change (Aug-Oct 2010), and 2492 (43.7%) in the first months after the policy change (Feb-Apr 2011). Odds ratios for being up-titrated according to time period were 1.02 [0.95-1.09] in Aug-Oct 2010 (before policy change) and 0.84 [0.78-0.90] in Feb-Apr 2011 (after policy change), compared with May-Jul 2010 (reference).

CONCLUSION: Probability of being up-titrated in ARB treatment was reduced 20% following changes in drug reimbursement policies.

Original languageEnglish
JournalPharmacoepidemiology and Drug Safety
Volume23
Issue number12
Pages (from-to)1281-7
Number of pages7
ISSN1053-8569
DOIs
Publication statusPublished - Dec 2014

ID: 45027550